Triple threat vaccine aims to shield seniors from three winter viruses
NCT ID NCT07295028
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new vaccine called VXB-251 in 240 healthy adults aged 60-83. The vaccine is designed to protect against three viruses that can cause serious lung infections: RSV, hMPV, and PIV3. Researchers will check if the vaccine is safe and how well it triggers the immune system, comparing it to existing vaccines and a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emeritus Research
Camberwell, Australia
-
Momentum Clinical Research
Darlinghurst, Australia
-
University of Sunshine Coast, South Bank
Brisbane, Australia
-
University of the Sunshine Coast
Morayfield, Australia
-
University of the Sunshine Coast, Sippy Downs
Sippy Downs, Australia
-
Veritus Research
Melbourne, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates